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Despite availability and administration of numerous antiepileptic
drugs (AEDs) nearly 15% of childhood epilepsy cases are resistant to
treatment; in traditional medicine however Nigella sativa L. (Black
seed) has been known for its anticonvulsant effects.
Materials and Methods:
In this double–blind clinical trial conducted on children with refractory
epilepsy we administered the aqueous extract of black seed as an
adjunct therapy and compared the effects with those of a placebo.
The study was performed between Sep 2003 and Nov 2004. The
subjects received either extract or placebo for a period of four weeks
and between these two periods for two weeks they received only
their pre-existing anti-epileptic drugs (AEDs).
Results:
The mean frequency of seizures decreased significantly during
treatment with extract, (p-value =0/007).
Conclusion:
It can be concluded that the water extract of Nigella sativa L. has
antiepileptic effects in children with refractory seizures that do not
respond to known AEDS.
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Despite administration of numerous antiepileptic drugs (AEDs) nearly 15% of
childhood epilepsy cases are resistant to treatment; these drugs fail to provide
adequate control of epileptic seizures and do not prevent progressive epileptogenic
changes (1,2). Recurrent seizures are still common clinical problems of hospitalized
pediatric patients (3).
Black cumin seed (botanical name is Nigella sativa L, Ranulacea family) or “Black
seed” for short; although believed to be indigenous the Mediterranean region, has
been cultivated in other parts of the world; through the years it has played an
important role in ancient Islamic medical practice. Much research is available on
its various therapeutic effects such as anti cancer (4), diuretic and hypotensive
effects (5), antihistaminic (6,7), antihypertensive (8), hypoglycemic (9) anti-
inflammatory, analgesic (10), antifungal and antibacterial (11,12). The oil is useful
in diseases
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in which free radicals are involved, e.g. anoxia and
ischemia of brain and heart as well as arteriosclerosis,
rheumatism and cancer (8,11,13,14,15).
In ancient Islamic medicine, Nigella sativa (Black cumin)
was known for its anticonvulsant effects. (16) Black
seed, in particular its major constituent thmoquinine,
have recently shown antiepileptic effects in mice. (17,18).
Furthermore several studies based on the toxicity of
black seed have been reported. It has been shown that
there were no toxic effects when Nigella sativa seed oil
was given to the mouse via the stomach; it has been also
reported that the nigella seed powder does not produce
any toxic effect when given to rabbit again by gastric
intubation (19). Also acute and chronic toxicity of Nigella
sativa fixed oil was investigated in rats and mice and
there were no evidence of toxicity (20) In this study we
have assessed oral administration of black seed aqueous
(soxhlet) extract as an adjunct to AEDs in a double-blind
clinical trial and compared the results with those of a
placebo.
Materials &Methods:
This pilot study was performed between Sep 2003 and
Nov 2004, in a tertiary referral center (Ghaem medical
center, Mashhad, Iran) Black cumin seeds were collected
from the southern part of the Khorasan province in Iran.
Patients and their relatives were advised that black seed
extract was registered for sale in USA as an immune
modulator (21), but without proven efficacy in epilepsy
and asked to give informed consent.
To be included in this pilot study, patients had to have
intractable epilepsy according to definition. (22),
occurrence of at least one seizure during the four-week
baseline period, relative absence of confounding illnesses,
constant antiepileptic treatment at least one month before
the study.
Exclusion criteria were history of status epilepticus within
the three months prior to the first visit, history of pseudo
seizures, seizures that due to their fast and repetitive
nature could not reliably be counted, current renal and
cardiac or hepatic dysfunction and lack of co-operation.
Patients who, qualified for the inclusion criteria, were
selected in sequential order of presentation from the
routine clinical caseload. Based on their type of seizures
and poor control with established AEDs, they were
selected over a consecutive period of 11 months; in this
period of time 23 patients were enrolled, but only 20
completed the study. The number of patients was deemed
to be a sufficient sample size of a pilot study.
Initially, prior to enrollment, each child underwent clinical
examinations, both general and systemic. Patients were
visited once a week throughout the study and all
information related to the number of seizures, history of
duration of, or possible changes in, seizures was obtained
from the parents. The clinicians were made familiar with
the nature and treatment history of patient's epilepsy.
Diagnosis of intractable seizures was made prior to the
study and type of seizures were categorized according
to ILAE classification (23,24).
Patients were provided with the syrup free of charge;
they received either extract or placebo at the dose of 0/4
ml/kg/8h for four-weeks and after a period of wash –out
(2 weeks) they received the other (extract or placebo for
the same period). The dosage of concomitant AEDs was
maintained throughout the treatment period. Throughout
these periods, the number, type and duration of seizures
were registered; in addition any adverse effects that
occurred were reported to the clinician and his assistant.
This protocol provided a uniform measure of seizure
frequency for comparison and contrast. At the end of
each period (placebo or extract) the degree of parental
satisfaction was assessed.
The study was reviewed and approved by the Research
and Ethics Committee of Mashhad University of Medical
Sciences of Iran.
All analysis was made using the SPSS statistical software
package and probability value of less than 0.05 was
considered statistically significant.
Results:
20 patients were eventually enrolled for the pilot study
(10 girls and 10 boys), ranging in age from 13months to
13 years (mean 66.95   45.39 months).
Seizure types were: 4 patients- generalized tonic-clonic,
8 myoclonic, 2 complex partial seizures, 1 polymorphic
seizure, 3 absence, 1 myoclonic with generalized tonic-
clonic,1 tonic-clonic with infantile spasm attack. 25%
were mentally retarded or had abnormal findings in their
neurological examinations.
Electroencephalograms (EEGs) and Computed tomogram
(CT-Scans) were abnormal in 90% and 20% respectively.
Mean age of seizure onset was 19.15   23.06 months.
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Patients used between 2 and 5 AEDs at time of entry in to the study. Compliance with extract was found to be very
good, as verified by remaining syrup at the end of each week.
The mean frequency of seizures in children at the end of extract period decreased from 5.78   7.2 seizures / day before
initiation of the study, to 4.21  5.77 seizures/day. At the end of the placebo period, mean frequency of seizures reached
to 6.14  6.75 seizures / day. The results of Friedman statistical test on these data showed a significant difference in
seizure frequency between extract period and other periods (Pvalue <0/001). Since the number of seizures in children
varied widely, there was a need for testing of data using a non- parametric statistical test, independent of the mean,
and hence the “Wilcoxon test” was used, the results demonstrating a significant difference between the extract period
and the period before initiation of the study, with p value of 0.007. Data from these two periods were compared
weekly with the Wilcoxon test; it seems that a statisticallysignificant difference between extract and placebo period.
(Table 1)
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The degree of parental satisfaction at the end of extract period and placebo period also showed a significant difference.
(Table-2).
Table-1: Results of the Wilcoxon test for frequency of seizures/day
Table-2: Parental satisfaction at the end of each period
During this study 3 patients reported adverse effects. One patient was constipated in the 2nd and 3rd weeks of the
extract period; in another, the parents reported increased laughing at the time of seizure, during the placebo period;
in the third, maculopapular rash appeared on the trunk on day 28.
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Discussion
Recurrent seizures and intractable epilepsies are common
clinical problems of hospitalized pediatric patients,
constituting a considerable number of outpatients referring
to pediatric neurology clinics. In spite of advances in the
treatment of epilepsy, a significant number of children
with epilepsy do not respond appropriately to antiepileptic
drugs (AEDs) (1,3).
Although an intensive search of literature failed to reveal
any clinical trial on the anticonvulsant effects of Nigella
sativa L on humans, the same effect in thymoquinine,
the major constituent of Nigella sativa l. have been
investigated in mice using pentylenetetrazole (PTZ)- and
maximal electroshock (MES)- induced seizure models.
In this study thymoquinone did exhibit anticonvulsant
activity in the PTZ – induced seizure model, but no
similar activity was seen in the MES model (17).
Generally, compounds with the anticonvulsant activity
in petit mal epilepsy, are effective in PTZ – induced
seizure models and drugs that possess anticonvulsant
activity in MES, may be considered as an effective against
grand mal epilepsy (25). It can hence be concluded that
thymoquinone may be useful in petit mal epilepsy, through
an opioid–mediated increase in the GABAergic tone
mechanism (17).Recently anticonvulsant and antioxidant
effects of Nigella sativa oil against PTZ-induced kindling
in mice were investigated, this study clearly demonstrated
a potent anticonvulsant property for Nigella sativa oil
against the development of kindling consequences in
PTZ-kindled mice, and was more potent as an
anticonvulsant agent than Valporate when they were
compared experimentally. The mechanism for the
anticonvulsant effect seems to be correlated with the
antioxidative effect. (18).
In our study, during the extract period, the mean of
seizures decreased gradually, whereas this was not so in
the placebo period.
At the end of the fourth week of the Nigella sativa period,
3 children had become seizure free; two of them had
myoclonic seizures. In one patient with Lennox-Gastaut
the number of seizures in the extract period was more
than in the placebo period. Results of our study showed
that aqueous extract of Nigella sativa has and
anticonvulsant effect, which may be explained by
thymoquinone the major constituent of Nigella sativa
seeds. Furthermore oil and fatty acids of Nigella sativa
seeds seem to play a role in this effect.
Conclusion
On the basis of the above observations, it may be
concluded that the aqueous extract of Nigella sativa L.
has anticonvulsant effects and can improve seizure control
in children suffering from refractory epilepsy. There is
however the need for more extensive trials to be conducted
in such patients to confirm these preliminary findings.
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